CelLBxHealth Valuation Multiples

Discover CelLBxHealth's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Genematrix, Biosynex, Elbit Imaging, Cheelcare and more.

CelLBxHealth Overview

About CelLBxHealth

CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.


Founded

2003

HQ

United Kingdom

Employees

119

Financials (LTM)

Revenue: $2M
EBITDA: ($12M)

EV

$19M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

CelLBxHealth Financials

CelLBxHealth reported last 12-month revenue of $2M and negative EBITDA of ($12M).

In the same LTM period, CelLBxHealth generated $2M in gross profit, ($12M) in EBITDA losses, and had net loss of ($14M).


CelLBxHealth P&L

In the most recent fiscal year, CelLBxHealth reported revenue of $2M and EBITDA of ($18M).

CelLBxHealth is unprofitable as of last fiscal year, with gross margin of 62%, EBITDA margin of (1001%), and net margin of (1444%).

See analyst estimates for CelLBxHealth
LTMLast FY202320242025202620272028
Revenue$2M$2M$3M$4M$2M
Gross Profit$2M$1M$2M$2M$1M
Gross Margin69%62%70%62%62%
EBITDA($12M)($18M)($26M)($18M)($18M)
EBITDA Margin(473%)(1001%)(869%)(455%)(1001%)
EBIT Margin(620%)(1140%)(936%)(541%)(1140%)
Net Profit($14M)($26M)($27M)($19M)($26M)
Net Margin(586%)(1444%)(921%)(497%)(1444%)

Financial data powered by Morningstar, Inc.

CelLBxHealth Stock Performance

CelLBxHealth has current market cap of $21M, and enterprise value of $19M.


CelLBxHealth's stock price is $0.02.

CelLBxHealth has an EPS (earnings per share) of $-0.02.

See more trading valuation data for CelLBxHealth
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$19M$21M-0.1%---$-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

CelLBxHealth Valuation Multiples

CelLBxHealth trades at 7.8x EV/Revenue multiple, and (1.6x) EV/EBITDA.

See NTM and 2027E valuation multiples for CelLBxHealth

CelLBxHealth Financial Valuation Multiples

As of August 14, 2026, CelLBxHealth has market cap of $21M and EV of $19M.

CelLBxHealth has a P/E ratio of (1.5x).

LTMLast FY202320242025202620272028
EV/Revenue7.8x10.4x6.4x4.9x10.4x
EV/EBITDA(1.6x)(1.0x)(0.7x)(1.1x)(1.0x)
EV/EBIT(1.3x)(0.9x)(0.7x)(0.9x)(0.9x)
EV/Gross Profit11.3x16.9x9.2x7.9x16.9x
P/E(1.5x)(0.8x)(0.8x)(1.1x)(0.8x)
EV/FCF(1.8x)(1.5x)(0.9x)(1.0x)(1.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified CelLBxHealth Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

CelLBxHealth Margins & Growth Rates

CelLBxHealth grew revenue by 56% but EBITDA decreased by 62% in the last fiscal year.

In the most recent fiscal year, CelLBxHealth reported gross margin of 62%, EBITDA margin of (1001%), and net margin of (1444%).

See estimated margins and future growth rates for CelLBxHealth

CelLBxHealth Margins

Last FY202420252026202720282029
Gross Margin62%62%62%71%
EBITDA Margin(1001%)(455%)(1001%)(243%)
EBIT Margin(1140%)(541%)(1140%)(286%)
Net Margin(1444%)(497%)(1444%)(252%)
FCF Margin(704%)(485%)(704%)(281%)

CelLBxHealth Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth56%31%(53%)56%
Gross Profit Growth80%16%(53%)80%
EBITDA Growth(62%)(31%)4%(62%)
EBIT Growth(61%)(24%)(0%)(61%)
Net Profit Growth(73%)(29%)37%(73%)
FCF Growth(38%)(8%)(32%)(38%)

Data powered by FactSet, Inc. and Morningstar, Inc.

CelLBxHealth Operational KPIs

CelLBxHealth's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.

CelLBxHealth's Rule of 40 is (187%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CelLBxHealth's Rule of X is (104%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for CelLBxHealth
LTMLast FY202320242025202620272028
Rule of 40(337%)(187%)---
Bessemer Rule of X(132%)(104%)---
Revenue per Employee-$0.0M---
Opex per Employee-$0.2M---
G&A Expenses to Revenue-55%17%16%55%
R&D Expenses to Revenue-95%113%62%95%
Opex to Revenue-1202%1006%603%1202%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

CelLBxHealth Competitors

CelLBxHealth competitors include Genematrix, Biosynex, Elbit Imaging, Cheelcare, Finemedix, Trajan Group Holdings, Rhythm Biosciences, Lifeward, Promimic and Polyrizon.

Most CelLBxHealth public comparables operate across Medical Devices, Diagnostics & Genomics, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Genematrix1.6x-(14.5x)-
Biosynex0.8x-59.8x-
Elbit Imaging----
Cheelcare19.4x-(32.2x)-
Finemedix2.9x-(18.4x)-
Trajan Group Holdings0.4x0.4x9.1x5.1x
Rhythm Biosciences1082.4x-(7.6x)-
Lifeward0.9x0.8x(1.2x)-

This data is available for Pro users. Sign up to see all CelLBxHealth competitors and their valuation data.

Start Free Trial

CelLBxHealth VC Funding History

Before going public, CelLBxHealth raised $300K in total equity funding, across 1 round.


CelLBxHealth Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Mar-15Pre-seed-$300K--

Acquisitions by CelLBxHealth

CelLBxHealth has acquired 1 company to date.

Last acquisition by CelLBxHealth was on November 1st 2017. CelLBxHealth acquired Axela, Inc for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by CelLBxHealth

Axela, Inc
Description
Axela, Inc. is a Toronto-based life sciences firm delivering multiplex analysis platforms for proteins, DNA, and RNA in biomarker testing and infectious disease research. Its commercial portfolio includes bead-based instruments, sensors, chips, reagents, and software applications, distributed globally through life sciences and clinical partners. Specific biomarker assays and methods are licensed to diagnostic and industry collaborators to advance personalized medicine.
HQ CountryCanada
HQ City
Toronto
Deal Date1 Nov 2017
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all CelLBxHealth acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About CelLBxHealth

When was CelLBxHealth founded?CelLBxHealth was founded in 2003.
Where is CelLBxHealth headquartered?CelLBxHealth is headquartered in United Kingdom.
How many employees does CelLBxHealth have?As of today, CelLBxHealth has over 119 employees.
Is CelLBxHealth publicly listed?Yes, CelLBxHealth is a public company listed on London Stock Exchange.
What is the stock symbol of CelLBxHealth?CelLBxHealth trades under CLBX ticker.
When did CelLBxHealth go public?CelLBxHealth went public in 2004.
Who are competitors of CelLBxHealth?CelLBxHealth main competitors include Genematrix, Biosynex, Elbit Imaging, Cheelcare, Finemedix, Trajan Group Holdings, Rhythm Biosciences, Lifeward, Promimic, Polyrizon.
What is the current market cap of CelLBxHealth?CelLBxHealth's current market cap is $21M.
What is the current revenue of CelLBxHealth?CelLBxHealth's last 12 months revenue is $2M.
What is the current revenue growth of CelLBxHealth?CelLBxHealth revenue growth (NTM/LTM) is 136%.
What is the current EV/Revenue multiple of CelLBxHealth?Current revenue multiple of CelLBxHealth is 7.8x.
Is CelLBxHealth profitable?No, CelLBxHealth is not profitable.
What is the current EBITDA of CelLBxHealth?CelLBxHealth has negative EBITDA and is not profitable.
What is CelLBxHealth's EBITDA margin?CelLBxHealth's last 12 months EBITDA margin is (473%).
What is the current EV/EBITDA multiple of CelLBxHealth?Current EBITDA multiple of CelLBxHealth is (1.6x).
What is the current FCF of CelLBxHealth?CelLBxHealth's last 12 months FCF is ($10M).
What is CelLBxHealth's FCF margin?CelLBxHealth's last 12 months FCF margin is (426%).
What is the current EV/FCF multiple of CelLBxHealth?Current FCF multiple of CelLBxHealth is (1.8x).
How many companies CelLBxHealth has acquired to date?As of August 2026, CelLBxHealth has acquired 1 company.
What was the largest acquisition by CelLBxHealth?None of the M&A deals CelLBxHealth has completed have disclosed valuations.
What companies CelLBxHealth acquired?CelLBxHealth acquired Axela, Inc.
In how many companies CelLBxHealth has invested to date?CelLBxHealth hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to CelLBxHealth

Lists including CelLBxHealth

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial